HomeENGLISH MAGAZINEProstate cancer: a simple urine test becomes feasible reality

Prostate cancer: a simple urine test becomes feasible reality

Prostate cancer is the most common cancer among men in the UK with 47,000 new cases diagnosed annually. This type of cancer tends to develop slowly and may never cause any problems. It generally does not require treatment over the course of a man’s lifetime, but men with aggressive cancer do require treatment to prevent it from spreading. However, doctors have difficulty predicting whether the cancer will become aggressive, which makes it difficult to decide on the appropriate treatment approach. Currently, when a man visits their doctor and presents with symptoms such as frequent urination during the night, they are given a PSA blood test, a digital rectal examination (DRE), an MRI scan or a prostate biopsy. However, up to three-quarters of men with a high PSA level who have a biopsy do not actually have prostate cancer. This means many men experience unnecessary worry, monitoring and treatment, so routine prostate screening is not yet offered to men. Anyway, invasive follow-ups could be a thing of the past. Researchers have developed a new urine test to diagnose aggressive forms of prostate cancer, which could mean an end to the unnecessary treatment of men with non-aggressive cancers. The test, which has been developed by researchers at the University of East Anglia and Norfolk and Norwich University Hospital, would allow doctors to differentiate between patients with aggressive prostate cancer who would need surgery and those with cancer that would progress so slowly that patient monitoring would be enough.

The test, which is called ‘PUR’ (Prostate Urine Risk), would enable doctors to predict whether treatment would be needed up to five years earlier than conventional methods do. Lead author Shea Connell and colleagues hope that the breakthrough will result in many low-risk men avoiding unnecessary biopsies, active surveillance, and follow-up. A policy of ‘active surveillance’ has been developed as a way to combat this uncertainty but it requires invasive follow-ups and constant reminders that a patient has a cancer with an uncertain natural history. Meanwhile, 15% of men without a raised PSA level are found to have cancer after all and in 15% of those cases, the cancer is aggressive. Now, Shea and colleagues have developed the new PUR test using machine learning to assess gene expression in urine samples taken from 537 trial participants. By assessing the expression of 167 genes, the team found that a combination of 35 genes served as a more accurate risk signature for the disease. Previous urine biomarkers tests have only been designed for specific purposes such as checking for prostate cancer when a patient has a repeat biopsy. The new test, on the other, identifies four PUR risk signatures that reliably enable men to be stratified by risk (low, intermediate or high) and determine how aggressive the cancer is going to be. The researchers say that looking for the risk signatures in urine will identify patients who do not need a biopsy, even if they initially appear to be at risk.

The test is among a number of new tests, including other urine tests, as well as scans and blood tests, that are being developed by scientists in efforts to improve detection of the disease. Experts say a combination of such checks may eventually prove to be the best approach. Connell says a larger trial is now planned. He hopes the test could become available as an add-on to PSA testing within the next three years. Dr. Jeremy Clark, co-lead Author of the project, explained and commented: “Prostate cancer is more commonly a disease men die with rather than from. Unfortunately, we currently lack the ability to tell which men diagnosed with prostate cancer will need radical treatment and which men will not. This research shows that our test could be used to not only diagnose prostate cancer without the need for an invasive needle biopsy but to identify a patient’s level of risk. This means that we could predict whether or not prostate cancer patients already on active surveillance would require treatment. The really exciting finding was that the test could predict disease progression up to five years earlier than when standard clinical methods are used. It also identified men who were eight times less likely to require treatment within five years of being diagnosed. If this test was to be used in the clinic, large numbers of men could avoid an unnecessary initial biopsy and the repeated, invasive follow-up of men with low-risk disease could be drastically reduced.”

  • Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.

Scientific references

Connell SP, Hanna M et al., Clark J. BJU Internat. 2019 May 20.

O’Reilly E et al., Perry AS. JCO Precision Oncol. 2019; 2019.

Zhao F et al., Bapat B. Clin Epigenetics. 2018 Nov 23;10(1):147.

Pellegrini KL, Patil D et al. Prostate. 2017 Jun; 77(9):990-99. 

Dott. Gianfrancesco Cormaci
- Laurea in Medicina e Chirurgia nel 1998 (MD Degree in 1998) - Specialista in Biochimica Clinica nel 2002 (Clinical Biochemistry residency in 2002) - Dottorato in Neurobiologia nel 2006 (Neurobiology PhD in 2006) - Ha soggiornato negli Stati Uniti, Baltimora (MD) come ricercatore alle dipendenze del National Institute on Drug Abuse (NIDA/NIH) e poi alla Johns Hopkins University, dal 2004 al 2008. - Dal 2009 si occupa di Medicina personalizzata. - Guardia medica presso strutture private dal 2010 - Detentore di due brevetti sulla preparazione di prodotti gluten-free a partire da regolare farina di frumento immunologicamente neutralizzata (owner of patents concerning the production of bakery gluten-free products, starting from regular wheat flour). - Responsabile del reparto Ricerca e Sviluppo per la società CoFood s.r.l. (leader of the R&D for the partnership CoFood s.r.l.) - Autore di un libro riguardante la salute e l'alimentazione, con approfondimenti su come questa condizioni tutti i sistemi corporei. - Autore di articoli su informazione medica e salute sui siti web salutesicilia.com, medicomunicare.it e in lingua inglese sul sito www.medicomunicare.com
- Advertisment -